These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35131879)

  • 1. Clinical Performance of the BD Onclarity Extended Genotyping Assay for the Management of Women Positive for Human Papillomavirus in Cervical Cancer Screening.
    Volesky KD; Magnan S; Mayrand MH; Isidean SD; El-Zein M; Comète E; Franco EL; Coutlée F
    Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):851-857. PubMed ID: 35131879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population.
    Wong OGW; Ng IFY; Tsun OKL; Pang HH; Ip PPC; Cheung ANY
    J Clin Microbiol; 2019 Dec; 57(12):. PubMed ID: 31511337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
    Song F; Du H; Wang C; Huang X; Wu R;
    PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
    Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
    Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
    Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
    Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial.
    Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews JA
    Gynecol Oncol; 2023 Mar; 170():143-152. PubMed ID: 36682092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States.
    Bukowski A; Hoyo C; Hudgens MG; Brewster WR; Valea F; Bentley RC; Vidal AC; Maguire RL; Schmitt JW; Murphy SK; North KE; Smith JS
    Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1564-1571. PubMed ID: 35654413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
    Stoler MH; Parvu V; Yanson K; Andrews J; Vaughan L
    Gynecol Oncol; 2023 Jul; 174():68-75. PubMed ID: 37149907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation testing with S5 for triage of high-risk HPV positive women.
    Adcock R; Nedjai B; Lorincz AT; Scibior-Bentkowska D; Banwait R; Torrez-Martinez N; Robertson M; Cuzick J; Wheeler CM;
    Int J Cancer; 2022 Oct; 151(7):993-1004. PubMed ID: 35477862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of human papillomavirus load, reflected by cycle threshold values, for the triage of HPV-positive self-samples in cervical cancer screening.
    Song F; Du H; Wang C; Huang X; Qu X; Wei L; Belinson JL; Wu R;
    J Med Screen; 2021 Sep; 28(3):318-324. PubMed ID: 32869705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p16/Ki67 dual stain triage versus cytology in primary human papillomavirus-based cervical cancer screening with limited genotyping.
    Trzeszcz M; Mazurec M; Jach R; Mazurec K; Kotkowska-Szeps I; Kania M; Wantuchowicz M; Wasowska J; Duczek-Polakiewicz M; Rozmus P; Streb J; Halon A
    J Med Virol; 2023 Nov; 95(11):e29271. PubMed ID: 38009626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples.
    Ebisch RM; de Kuyper-de Ridder GM; Bosgraaf RP; Massuger LF; IntHout J; Verhoef VM; Heideman DA; Snijders PJ; Meijer CJ; van Kemenade FJ; Bulten J; Siebers AG; Bekkers RL; Melchers WJ
    Int J Cancer; 2016 Aug; 139(3):691-9. PubMed ID: 26991464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study.
    Hanley SJB; Fujita H; Aoyama-Kikawa S; Kasamo M; Torigoe T; Matsuno Y; Noriaki S;
    J Gynecol Oncol; 2021 Nov; 32(6):e86. PubMed ID: 34708593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology.
    Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews J
    Gynecol Oncol; 2019 Apr; 153(1):26-33. PubMed ID: 30638767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Performance of hrHPV Primary Screening Using Vaginal versus Cervical Samples to Detect High-grade Intraepithelial Lesions.
    King J; Flores YN; Meneses-León J; Hernández-Salazar S; Robles-Rivera K; Rivera-Paredez B; León-Maldonado L; Hernández-López R; Torres-Ibarra L; Lazcano-Ponce E; Salmerón J
    Cancer Prev Res (Phila); 2023 Dec; 16(12):681-687. PubMed ID: 37788346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology.
    Stoler MH; Wright TC; Parvu V; Yanson K; Eckert K; Kodsi S; Cooper C
    Am J Clin Pathol; 2019 Mar; 151(4):433-442. PubMed ID: 30649177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study.
    Dong L; Wang MZ; Zhao XL; Feng RM; Hu SY; Zhang Q; Smith JS; Qiao YL; Zhao FH
    Gynecol Oncol; 2018 Jan; 148(1):103-110. PubMed ID: 29169614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
    Xu L; Oštrbenk A; Poljak M; Arbyn M
    J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan.
    Chang CL; Ho SC; Su YF; Juan YC; Huang CY; Chao AS; Hsu ZS; Chang CF; Fwu CW; Chang TC
    Gynecol Oncol; 2021 May; 161(2):429-435. PubMed ID: 33757653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the performance of 2 human papillomavirus assays for a new use indication: a real-world evidence-based evaluation in the United States.
    Wheeler CM; Torrez-Martinez NE; Torres-Chavolla E; Parvu V; Andrews JC; Du R; Robertson M; Joste NE; Cuzick J;
    Am J Obstet Gynecol; 2024 Feb; 230(2):243.e1-243.e11. PubMed ID: 37806613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.